(1S,2R)-(+)-Norephedrine

Names

[ Name ]:
(1S,2R)-(+)-Norephedrine

[Synonym ]:
EINECS 238-900-2
dl-phenylpropanolamine
d-NOREPHEDRINE BASE
(1R,2S)-2-Amino-1-phenyl-1-propanol hydrochloride (1:1)
PHENYLPROPANOLAMINEBASE
d-Phenylpropanolamine
dl-NOREPHEDRINE BASE
MFCD00064411
Benzenemethanol, α-[(1S)-1-aminoethyl]-, (αR)-, hydrochloride (1:1)
dl-propadrine

Chemical & Physical Properties

[ Density]:
1.071g/cm3

[ Boiling Point ]:
288.1ºC at 760mmHg

[ Melting Point ]:
51-54ºC

[ Molecular Formula ]:
C₉H₁₃NO

[ Molecular Weight ]:
187.667

[ Exact Mass ]:
187.076385

[ PSA ]:
46.25000

[ LogP ]:
1.76750

Safety Information

[ Symbol ]:

GHS07

[ Signal Word ]:
Warning

[ Hazard Statements ]:
H302-H315-H319-H335

[ Precautionary Statements ]:
P261-P305 + P351 + P338

[ Personal Protective Equipment ]:
dust mask type N95 (US);Eyeshields;Gloves

[ Hazard Codes ]:
Xn: Harmful;

[ Risk Phrases ]:
R22;R36/37/38

[ Safety Phrases ]:
S26

[ RIDADR ]:
NONH for all modes of transport

[ WGK Germany ]:
3

[ HS Code ]:
2922199090

Synthetic Route

Click to get detail synthetic route

Precursor & DownStream

Precursor

DownStream

Customs

[ HS Code ]: 2922199090

[ Summary ]:
2922199090. other amino-alcohols, other than those containing more than one kind of oxygen function, their ethers and esters; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0%

Articles

The Psychostimulant Khat (Catha edulis) Inhibits CYP2D6 Enzyme Activity in Humans.

J. Clin. Psychopharmacol. 35 , 694-9, (2015)

The use of khat (Catha edulis) while on medication may alter treatment outcome. In particular, the influence of khat on the metabolic activities of drug-metabolizing enzymes is not known. We performed...

Solvent-free melting techniques for the preparation of lipid-based solid oral formulations.

Pharm. Res. 32(5) , 1519-45, (2015)

Lipid excipients are applied for numerous purposes such as taste masking, controlled release, improvement of swallowability and moisture protection. Several melting techniques have evolved in the last...

The Expected Net Present Value of Developing Weight Management Drugs in the Context of Drug Safety Litigation.

Pharmacoeconomics 33 , 749-63, (2015)

Following withdrawals, failures, and significant litigation settlements, drug product launches in the anti-obesity category slowed despite a large and growing unmet need. Litigation concerns, a more r...